FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072392504> ?p ?o ?g. }

• W2072392504 endingPage "1593" @default.
• W2072392504 startingPage "1593" @default.
• W2072392504 abstract "The use of escharotic or caustic pastes to treat skin cancer is based on the centuries-old observation that selected minerals and plant extracts may be used to destroy certain skin lesions. Zinc chloride and Sanguinaria canadensis (bloodroot) are 2 agents that are used as part of the Mohs chemosurgery fixed-tissue technique. The use of escharotics without surgery has been discredited by allopathic medicine but persists and is promoted among alternative practitioners. Patients may now purchase herbal supplements for the primary self-treatment of skin cancer, and physicians will see patients who elect this therapy for their skin cancers.We reviewed the history of escharotic use for skin disease and performed an Internet search for the availability and current use of escharotics. Our search located numerous agents for purchase via the Internet that are advertised as highly successful treatments for skin cancer. We report 4 cases from our practice in which escharotic agents were used by patients to treat basal cell carcinomas in lieu of the recommended conventional treatment. One patient had a complete clinical response, but had a residual tumor on follow-up biopsy. A second patient successfully eradicated all tumors, but severe scarring ensued. A third patient disagreed with us regarding his care and was lost to follow-up. One patient presented with a nasal basal cell carcinoma that healed for several years following treatment elsewhere with an escharotic agent but recurred deeply and required an extensive resection. The lesion has since metastasized.Escharotic agents are available as herbal supplements and are being used by patients for the treatment of skin cancer. The efficacy of these agents is unproven and their content is unregulated. Serious consequences may result from their use. Conventional medicine has an excellent track record in treating skin cancer. Physicians should recommend against the use of escharotic agents for skin cancer, and the Food and Drug Administration should be given the authority to regulate their production and distribution." @default.
• W2072392504 created "2016-06-24" @default.
• W2072392504 creator A5050563514 @default.
• W2072392504 creator A5077784486 @default.
• W2072392504 date "2002-12-01" @default.
• W2072392504 modified "2023-10-09" @default.
• W2072392504 title "Consequences of Using Escharotic Agents as Primary Treatment for Nonmelanoma Skin Cancer" @default.
• W2072392504 cites W1484668472 @default.
• W2072392504 cites W1974716440 @default.
• W2072392504 cites W2016019098 @default.
• W2072392504 cites W2038074763 @default.
• W2072392504 cites W2050965363 @default.
• W2072392504 cites W2334427329 @default.
• W2072392504 doi "https://doi.org/10.1001/archderm.138.12.1593" @default.
• W2072392504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12472348" @default.
• W2072392504 hasPublicationYear "2002" @default.
• W2072392504 type Work @default.
• W2072392504 sameAs 2072392504 @default.
• W2072392504 citedByCount "44" @default.
• W2072392504 countsByYear W20723925042012 @default.
• W2072392504 countsByYear W20723925042013 @default.
• W2072392504 countsByYear W20723925042014 @default.
• W2072392504 countsByYear W20723925042015 @default.
• W2072392504 countsByYear W20723925042016 @default.
• W2072392504 countsByYear W20723925042017 @default.
• W2072392504 countsByYear W20723925042018 @default.
• W2072392504 countsByYear W20723925042019 @default.
• W2072392504 countsByYear W20723925042020 @default.
• W2072392504 countsByYear W20723925042021 @default.
• W2072392504 countsByYear W20723925042023 @default.
• W2072392504 crossrefType "journal-article" @default.
• W2072392504 hasAuthorship W2072392504A5050563514 @default.
• W2072392504 hasAuthorship W2072392504A5077784486 @default.
• W2072392504 hasConcept C121608353 @default.
• W2072392504 hasConcept C126322002 @default.
• W2072392504 hasConcept C141071460 @default.
• W2072392504 hasConcept C142724271 @default.
• W2072392504 hasConcept C16005928 @default.
• W2072392504 hasConcept C2777789703 @default.
• W2072392504 hasConcept C2778334829 @default.
• W2072392504 hasConcept C2778804307 @default.
• W2072392504 hasConcept C3019992690 @default.
• W2072392504 hasConcept C71924100 @default.
• W2072392504 hasConceptScore W2072392504C121608353 @default.
• W2072392504 hasConceptScore W2072392504C126322002 @default.
• W2072392504 hasConceptScore W2072392504C141071460 @default.
• W2072392504 hasConceptScore W2072392504C142724271 @default.
• W2072392504 hasConceptScore W2072392504C16005928 @default.
• W2072392504 hasConceptScore W2072392504C2777789703 @default.
• W2072392504 hasConceptScore W2072392504C2778334829 @default.
• W2072392504 hasConceptScore W2072392504C2778804307 @default.
• W2072392504 hasConceptScore W2072392504C3019992690 @default.
• W2072392504 hasConceptScore W2072392504C71924100 @default.
• W2072392504 hasIssue "12" @default.
• W2072392504 hasLocation W20723925041 @default.
• W2072392504 hasLocation W20723925042 @default.
• W2072392504 hasOpenAccess W2072392504 @default.
• W2072392504 hasPrimaryLocation W20723925041 @default.
• W2072392504 hasRelatedWork W10191283 @default.
• W2072392504 hasRelatedWork W2029706239 @default.
• W2072392504 hasRelatedWork W2116661571 @default.
• W2072392504 hasRelatedWork W2140085404 @default.
• W2072392504 hasRelatedWork W2473425647 @default.
• W2072392504 hasRelatedWork W2921196406 @default.
• W2072392504 hasRelatedWork W3093398530 @default.
• W2072392504 hasRelatedWork W4235646789 @default.
• W2072392504 hasRelatedWork W4361252764 @default.
• W2072392504 hasRelatedWork W4384787935 @default.
• W2072392504 hasVolume "138" @default.
• W2072392504 isParatext "false" @default.
• W2072392504 isRetracted "false" @default.
• W2072392504 magId "2072392504" @default.
• W2072392504 workType "article" @default.